FDA has requested a meeting with Sanofi’s senior management to discuss a host of manufacturing problems – from inadequate sterility testing to the nesting of birds in air units – at two of the company’s facilities.
The call for a meeting with the company is uncommon and indicates the seriousness of the violations. Among current good...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?